Description: Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity. Target: Raf. Smiles: COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C. References: Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790

B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling. A mutation of B-Raf in exon 15 at codon 600 where a valine is substituted by glutamic acid (V600E) has been linked to melanoma. Encorafenib is a selective inhibitor of B-RafV600E mutant...